Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Cost-cutting, check. Now, it’s on to dealmaking, Teva chief says

February 6, 2015
Life sciences
Okay, pharma. Teva is ready to make some deals now. Really. It’s serious.
 
It’s a mantra that’s seen quite a bit of play since CEO Erez Vigodman took up the reins at the generics giant early last year. But now, after a year of focusing on cutting costs and debt, and turning things around at the struggling drugmaker, he really means it.
 
“In 2015 we are reorienting towards inorganic moves,” he said on the company’s fourth-quarter conference call, as quoted by Reuters. Translation: We’re shopping.
 
As he’s said before, Vigodman has his eye on emerging markets and complex generics, to name a couple of potential deal targets. Rumors about a Mylan merger have persisted, though plenty of analysts have their doubts about that one. Perrigo, the OTC-focused drugmaker now based in Ireland, or Sweden’s Meda could also make sense, industry watchers have suggested.
 
So far, Teva itself has been quiet on the acquisition front, despite the wave of deals that took pharma by storm in 2014. “Teva has a healthy business, but in this environment if you’re not doing deals, you’re probably not taking advantage of the opportunities that are out there,” Gabelli & Co. analyst Kevin Kedra told Bloomberg last month.
 
Whatever M&A moves Teva does ultimately make could help the company on its quest to return to growth–especially if they’re in the generics department. Last quarter, generics revenue fell 8% to $2.47 billion, propelling a 4.8% overall sales drop. The decline was in line with analyst expectations, Bloomberg said.
 
Teva’s generics sales also took a dip on the full year, despite contributions from knockoffs of AbbVie’s heart pill Niaspan and Merck’s  brain cancer drug Temodar.
 
By Carly Helfand
 

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach